Ludwig Institute for Cancer Research Limited

Wyeth

Universitè Catholique De Louvain

Argenx Bvba

Delphi Genetics S.a.

Medimmune Limited

Departemente D'immunologie Institut Henri Beaufour

Department D'immunologie Institut Henri Beaufour

Argenx Bv

Jean-Christophe Renauld

Pierre G Coulie

Laure Dumoutier

Thierry R Boon-Falleur

Pierre Van Der Bruggen

Jacques Van Snick

Catherine Druez

Claude Wildmann

Jamila Louhed

Sophie Lucas

Catherine Uyttenhove

Julia Cuende Villasur

Pierre Braquet

Aline Van Pel

Hans De Haard

Vincent Brichard

Sebastian Paul Van Der Woning

Michael Saunders

Bernard Lethe

Thomas Wolfel

Etienne DePlaen

Gitte De Boeck

Muriel Lemaire

Mary-Christine Many

Pascale Boel

Bernard Dugas

Jean M Mencia-Huerta

Laura Dumoutier

Pascale Bo{haeck Over (e)}l

Laurent Gillet

Alain Vanderplasschen

Yannick Nizet

Laurie Dumoutier

William Dall'Acqua

Cédric Szpirer

Paul Proost

Jo Van Damme

Jennifer Lynne Reed

Sophie Scohy

Francois Huaux

Dominique Lison

Francoise Cormont

Frederic Houssiau

Simon Hör

Helmut Fickenscher

Diane Lejeune

Jamila Louahed

The present invention relates to a protein binding to GARP in the presence of TGF-&#x3b2; and uses thereof.

Anti-GARP protein

Antibody against a complex between human GARP and latent TGF-&#x3b2;

Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment, homologous or orthologues protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.

Method for producing antibody using 'naked' expression vector expressing type II transmembrane fusion protein

The present invention relates to an antibody binding to the transmembrane protein 'glycoprotein A repetitions predominant' (GARP) in the presence of TGF-&#x3b2; and uses thereof.

Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody

Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment or homologous protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.

The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.

Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof

Interleukin-22 interacts with its receptor, referred to as IL-22R, and instigates a series of reactions, leading to activation of various molecules, such as JAK-1, Tyk2, and others. One can identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway, to identify agonists and antagonists. These, in turn, are useful therapeutic agents, where inappropriate expression of one of the activated molecules is at issue, and requires amelioration.

Method for identifying a substance which mediates interaction between interleukin 22 and an interleukin 22 receptor

The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.

Isolated soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

Recombinant anti-interleukin-9 antibodies

Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof

Isolated nucleic acid molecules encoding T cell derived inducible factors

The invention relates to new members of the Class II cytokine receptor family, such as LICR-2. The new member binds to AK155, and mediates STAT activation.

Isolated cytokine receptor LICR-2

A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.

Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens

Isolated nucleic acid molecule encoding peptides which form complexes with MHC molecules HLA-Cw*1601 and uses thereof

Growing community of inventors

Brussels, Belgium

Jean-Christophe Renauld